Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2023
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy TS ID 9716Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer [ID6187]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI-guided laser interstitial thermal therapy for early prostate cancerStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment TS ID 11928Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer TS ID 11933Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI guided transurethral high intensity ultrasound ablation of the prostateStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC